Navigation Links
Cholesterol Drug Shows Promise in Early Research
Date:11/15/2011

TUESDAY, Nov. 15 (HealthDay News) -- Preliminary trials indicate that a new drug designed to simultaneously boost good cholesterol while lowering bad cholesterol shows considerable promise, both on its own and in combination with standard statin medications.

The drug evacetrapib is part of a class of so-called "cholesteryl ester transfer protein (CETP) inhibitors."

Evacetrapib is the second CETP medication to undergo testing as a means to lower "bad" low-density lipoprotein cholesterol while raising "good" high-density lipoprotein cholesterol.

Testing of the first drug in this class -- Pfizer's torcetrapib -- ended badly. A 15,000-person trial of torcetrapib conducted several years ago revealed that the medication (administered in combination with the statin Lipitor) was associated with an elevated risk for cardiovascular complications and even death.

In that case, the trial was halted mid-stream and all patients were taken off the combination therapy immediately.

However, the failure of that drug has not discouraged researchers from continuing to explore the potential of CETP therapies. What's more, work with evacetrapib to date has unearthed no significant side effects, while suggesting that the drug can benefit patients both as an individual treatment and as part of a two-pronged approach in tandem with statins, according to the report published Nov. 16 in the Journal of the American Medical Association.

"These preliminary findings suggest that evacetrapib could be administered with statins and may yield potentially clinically important incremental effects on lipoproteins," Stephen J. Nicholls, of the department of cardiovascular medicine and the coordinating center for clinical research at the Cleveland Clinic in Ohio, and colleagues noted in a journal news release.

"The results of the current study provide the foundation for a large phase 3 clinical trial designed to assess the efficacy and safety of evacetrapib," the study authors added.

The most recent testing of evacetrapib involved almost 400 patients who, between April 2010 and January 2011, were being treated for having either elevated bad cholesterol or low good cholesterol levels in health centers across the United States and Europe.

The patients were divided into several groups. For about three months, some received various dosages of evacetrapib alone. Others received one of several statins, either alone or in combination with evacetrapib. Still others were given sugar pills (placebo pills).

The results: after 12 weeks of treatment, the team observed that patients receiving evacetrapib alone experienced a boost in good cholesterol of between roughly 54 and 129 percent. Among this group, bad cholesterol also dropped, between approximately 14 to 36 percent.

The investigators also found that when given a combination therapy involving both evacetrapib and a statin, patients experienced even greater reductions in bad cholesterol. This tandem approach, however, did not produce better results than evacetrapib alone in terms of raising good cholesterol.

Commenting on the study, Dr. Murray A. Mittleman, director of the Cardiovascular Epidemiology Research Unit with the Beth Israel Deaconess Medical Center at Harvard Medical School in Boston, approached the findings with caution.

"This class of medicines is interesting because they can raise good cholesterol, often quite markedly," Mittleman said. "And most studies show that this can prevent heart attacks. And at this point we don't have very many good drugs that can accomplish this."

"But of course, work with an earlier agent showed an increase in adverse events, and the development of that drug had to be stopped prematurely," Mittleman noted. "So while the initial findings with this drug are interesting, a lot of work still remains to find out if it does what we hope it will do, or if in fact it will end up being more harmful than beneficial."

The results of the research were released early online to coincide with the presentation of the study at the American Heart Association's annual meeting in Orlando, Fla.

More information

For more on cholesterol, visit the American Heart Association.

-- Alan Mozes

SOURCES: Murray A. Mittleman, M.D., director, Cardiovascular Epidemiology Research Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Journal of the American Medical Association, news release, Nov. 15, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New medication increases HDL cholesterol and decreases LDL cholesterol levels
2. Shot Might One Day Help Lower Cholesterol
3. New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11
4. Novel therapeutic target identified to decrease triglycerides and increase good cholesterol
5. FDA Approves First Combo Drug for Diabetes, Cholesterol
6. Raising good cholesterol levels reduces heart attack and stroke risk in diabetes patients
7. Cholesterol Deposits Around Eyes Linked to Heart Risk
8. Targeting cholesterol may help slow glioblastoma
9. Starving cancer cells of cholesterol might offer a new way to treat brain tumors
10. Targeting cholesterol to fight deadly brain cancers
11. High Cholesterol Might Be Linked to Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cholesterol Drug Shows Promise in Early Research
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
(Date:2/23/2017)... , February 23, 2017 According ... by Product (X-ray Imaging Digital, Analog), MRI (Closed, Open), ... MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) - ... studies the global market over the forecast period of ... ~USD 36.43 Billion by 2021, at a CAGR of ...
Breaking Medicine Technology: